| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M J Wallace, J L Wiley, B R Martin, R J DeLorenz. Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. European journal of pharmacology. vol 428. issue 1. 2002-04-02. PMID:11779037. |
we further establish, using the cannabinoid cb1 receptor specific antagonist n-(piperidin-1-yl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1h-pyrazole-3-carboxamidehydrochloride (sr141716a) (ad50 = 2.5 mg/kg), that the anticonvulsant effects of delta9-tetrahydrocannabinol and win 55,212-2 are cannabinoid cb1 receptor-mediated while the anticonvulsant activity of cannabidiol is not. |
2002-04-02 |
2023-08-12 |
Not clear |
| R I Wilson, R A Nicol. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature. vol 410. issue 6828. 2002-03-21. PMID:11279497. |
marijuana affects brain function primarily by activating the g-protein-coupled cannabinoid receptor-1 (cb1), which is expressed throughout the brain at high levels. |
2002-03-21 |
2023-08-12 |
Not clear |
| S A Varvel, R J Hamm, B R Martin, A H Lichtma. Differential effects of delta 9-THC on spatial reference and working memory in mice. Psychopharmacology. vol 157. issue 2. 2002-02-26. PMID:11594438. |
marijuana remains the most widely used illicit drug in the u.s., and recent attention has been given to putative therapeutic uses of marijuana and cannabinoid derivatives. |
2002-02-26 |
2023-08-12 |
mouse |
| Nissar A Darman. The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by delta(9)-tetrahydrocannabinol and other cannnabinoids. The Journal of pharmacology and experimental therapeutics. vol 300. issue 1. 2002-01-24. PMID:11752094. |
the nonpsychoactive cannabinoid, cannabidiol, was inactive. |
2002-01-24 |
2023-08-12 |
Not clear |
| S S Cui, R C Bowen, G B Gu, D K Hannesson, P H Yu, X Zhan. Prevention of cannabinoid withdrawal syndrome by lithium: involvement of oxytocinergic neuronal activation. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 21. issue 24. 2002-01-23. PMID:11739594. |
cannabis (i.e., marijuana and cannabinoids) is the most commonly used illicit drug in developed countries, and the lifetime prevalence of marijuana dependence is the highest of all illicit drugs in the united states. |
2002-01-23 |
2023-08-12 |
rat |
| S S Cui, R C Bowen, G B Gu, D K Hannesson, P H Yu, X Zhan. Prevention of cannabinoid withdrawal syndrome by lithium: involvement of oxytocinergic neuronal activation. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 21. issue 24. 2002-01-23. PMID:11739594. |
these results demonstrate that oxytocinergic neuronal activation plays a critical role in the action of lithium against the cannabinoid withdrawal syndrome in rats, thus providing a potentially novel strategy for the treatment of cannabis dependence in humans. |
2002-01-23 |
2023-08-12 |
rat |
| G Skopp, L Pötsc. [Passive exposure in detection of low blood and urine cannabinoid concentrations]. Archiv fur Kriminologie. vol 207. issue 5-6. 2002-01-03. PMID:11508050. |
the pharmacokinetics of smoked marijuana as well as experimental data on cannabinoid concentrations in plasma and urine samples following passive exposure are summarized. |
2002-01-03 |
2023-08-12 |
Not clear |
| E Gordon, O Devinsk. Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia. vol 42. issue 10. 2001-12-28. PMID:11737161. |
some evidence suggests that marijuana and its active cannabinoids have antiepileptic effects, but these may be specific to partial or tonic-clonic seizures. |
2001-12-28 |
2023-08-12 |
human |
| M D Van Sickle, L D Oland, W Ho, C J Hillard, K Mackie, J S Davison, K A Sharke. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology. vol 121. issue 4. 2001-12-05. PMID:11606489. |
marijuana and other cannabinoids are effective anti-emetics. |
2001-12-05 |
2023-08-12 |
Not clear |
| S J Tsai, Y C Wang, C J Hon. Association study between cannabinoid receptor gene (CNR1) and pathogenesis and psychotic symptoms of mood disorders. American journal of medical genetics. vol 105. issue 3. 2001-12-04. PMID:11353438. |
in brain, the main active ingredient of cannabis acts via the cannabinoid cb1 receptor (cnr1) which is located on chromosome 6q14-15. |
2001-12-04 |
2023-08-12 |
Not clear |
| L Fattore, G Cossu, C M Martellotta, W Fratt. Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats. Psychopharmacology. vol 156. issue 4. 2001-12-04. PMID:11498718. |
delta9-tetrahydrocannabinol (delta9-thc), the main psychoactive ingredient of marijuana, as well as synthetic cannabinoid (cb1) receptor agonists, has led to negative or equivocal results when tested with the intravenous self-administration procedure, the best validated behavioural model for evaluating abuse liability of drugs in experimental animals. |
2001-12-04 |
2023-08-12 |
mouse |
| A Ménétrey, M Augsburger, C Giroud, P Mangi. [Cannabis and automobile driving]. Praxis. vol 90. issue 34. 2001-12-04. PMID:11552320. |
in forensic practice, cannabis impairment of driving performance must be related to cannabinoids blood concentrations. |
2001-12-04 |
2023-08-12 |
Not clear |
| L N Voruganti, P Slomka, P Zabel, A Mattar, A G Awa. Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry research. vol 107. issue 3. 2001-12-04. PMID:11566433. |
this observation offers a plausible biological explanation for the psychotogenic effects of cannabis in vulnerable individuals, and also raises speculations about an interaction between cannabinoid and dopaminergic systems in the brain reward pathways. |
2001-12-04 |
2023-08-12 |
Not clear |
| A S Ric. Cannabinoids and pain. Current opinion in investigational drugs (London, England : 2000). vol 2. issue 3. 2001-12-04. PMID:11575713. |
recent advances have dramatically increased our understanding of cannabinoid pharmacology: the psychoactive constituents of cannabis sativa have been isolated, synthetic cannabinoids described and an endocannabinoid system identified, together with its component receptors, ligands and their biochemistry. |
2001-12-04 |
2023-08-12 |
Not clear |
| L Ferraro, M C Tomasini, T Cassano, B W Bebe, A Siniscalchi, W T O'Connor, P Magee, S Tanganelli, V Cuomo, T Antonell. Cannabinoid receptor agonist WIN 55,212-2 inhibits rat cortical dialysate gamma-aminobutyric acid levels. Journal of neuroscience research. vol 66. issue 2. 2001-12-04. PMID:11592127. |
these findings suggest that cannabinoids decrease cortical gaba levels in vivo, an action that might underlie some of the cognitive and behavioral effects of acute exposure to marijuana. |
2001-12-04 |
2023-08-12 |
rat |
| R N Kumar, W A Chambers, R G Pertwe. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia. vol 56. issue 11. 2001-12-04. PMID:11703238. |
pharmacological actions and therapeutic uses of cannabis and cannabinoids. |
2001-12-04 |
2023-08-12 |
Not clear |
| T Yamaguchi, Y Hagiwara, H Tanaka, T Sugiura, K Waku, Y Shoyama, S Watanabe, T Yamamot. Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice. Brain research. vol 909. issue 1-2. 2001-10-11. PMID:11478928. |
in the present study, we examined the effects of endogenous ligand 2-arachidonoylglycerol (2-ag) on naloxone-precipitated withdrawal in morphine-dependent mice, in comparison with that of two cannabinoid agonists, an ingredient of cannabis sativa delta(8)-tetrahydrocannabinol (delta(8)-thc) and the synthetic cannabinoid cb1 receptor agonist hu-210. |
2001-10-11 |
2023-08-12 |
mouse |
| E Valjent, C Pagès, M Rogard, M J Besson, R Maldonado, J Caboch. Delta 9-tetrahydrocannabinol-induced MAPK/ERK and Elk-1 activation in vivo depends on dopaminergic transmission. The European journal of neuroscience. vol 14. issue 2. 2001-10-11. PMID:11553284. |
it is now well established that central effects of delta 9-tetrahydrocannabinol (thc), the main psychoactive component of marijuana, are mediated by cb1 cannabinoid receptors. |
2001-10-11 |
2023-08-12 |
Not clear |
| T Maejima, T Ohno-Shosaku, M Kan. Endogenous cannabinoid as a retrograde messenger from depolarized postsynaptic neurons to presynaptic terminals. Neuroscience research. vol 40. issue 3. 2001-09-13. PMID:11448511. |
cannabinoid receptors are the molecular targets for the active component delta(9)-tetrahydrocannabinol of marijuana and hashish, and constitute a major family of g protein-coupled seven-transmembrane-domain receptors. |
2001-09-13 |
2023-08-12 |
Not clear |
| A H Lichtman, J L Poklis, A Poklis, D M Wilson, B R Marti. The pharmacological activity of inhalation exposure to marijuana smoke in mice. Drug and alcohol dependence. vol 63. issue 2. 2001-08-30. PMID:11376914. |
although the majority of cannabinoid users smoke marijuana, the preponderance of laboratory animal research is based on administration of delta9-tetrahydrocannabinol (delta9-thc) or other cannabinoid agents via injection. |
2001-08-30 |
2023-08-12 |
mouse |